220955-78-2

Basic information

• Product Name: 4-(4-phenylpiperazin-1-yl)benzaldehyde
• Synonyms: 4-(4-phenylpiperazin-1-yl)benzaldehyde
• CAS NO: 220955-78-2
• Molecular Weight: 266.343
• Mol File: 220955-78-2.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: 4-(4-phenylpiperazin-1-yl)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-phenylpiperazin-1-yl)benzaldehyde(220955-78-2)
• EPA Substance Registry System: 4-(4-phenylpiperazin-1-yl)benzaldehyde(220955-78-2)

Safety Data

• Hazardous Substances Data: 220955-78-2(Hazardous Substances Data)

Upstream product

• 92-54-6 4-phenyl-1-piperazine 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 1400538-20-6 1-(1H-benzo[d]imidazol-5-yl)-5-(4-(4-phenylpiperazin-1-yl)phenyl)pyrrolidine-2,4-dione 
• 1426121-76-7 C₄₂H₅₄N₆ 

Relevant articles and documents

Design, synthesis, in-silico and biological evaluation of novel donepezil derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease

A novel series of donepezil based multi-functional agents “(E)-5,6-dimethoxy-2-(4-(4-substituted piperazin-1-yl)benzylidene)-2,3-dihydro-1H-inden-1-ones” have been designed and synthesized as potential anti-Alzheimer's agents. In-vitro studies revealed th

Novel benzimidazole-acrylonitrile hybrids and their derivatives: Design, synthesis and antimycobacterial activity

This paper reports the synthesis and evaluation of some benzimidazole-acrylonitrile hybrid derivatives for their in vitro antimycobacterial activities against Mycobacterium tuberculosis H37Rv. Among the derivatives studied, 3b was found to be the most active compound with MIC of 0.78 μg/mL against M. tuberculosis. This is a quite good activity compared with ethambutol (MIC = 1.56 μg/mL). Moreover, 3b showed 2.8 log fold reduction in bacterial count of dormant forms of mycobacterium which is more potent than first line drugs isoniazid, ciprofloxacin, rifampicin and moxifloxacin. Having activities against both active and dormant forms of M. tuberculosis, 3b may be a useful candidate for the development of new drugs to treat tuberculosis.

Synthesis and biological evaluation of new thiosemicarbazone derivative schiff bases as monoamine oxidase inhibitory agents

Twenty-six novel thiosemicarbazone derivative B1–B26 were synthesized via condensation reactions between the corresponding thiosemicarbazides and aldehydes. The chemical characterization of the compounds was carried out by infrared (IR), mass (MS), proton and carbon nuclear magnetic resonance (1H- and 13C-NMR) spectroscopic analyses. The compounds were investigated for their monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) inhibitory activity and most of them were more potent against MAO-A enzyme when compared with MAO-B enzyme. N-Cyclohexyl-2-[4-[(4-chlorophenyl)thio]benzylidene]hydrazine-1-carbothioamide (B24) was the most active compound against MAO-A. The enzyme kinetics study revealed that compound B24 has a reversible and competitive mode of binding. Interaction modes between compound B24 and MAO-A were clarified by docking studies. In addition, the favourable absorption, distribution, metabolism, and excretion (ADME) properties and non-toxic nature of compound B24 make this compound a promising MAO-A inhibitor.